首站-论文投稿智能助手
典型文献
Mechanisms and strategies to overcome immunotherapy resistance in hepatobiliary malignancies
文献摘要:
Unprecedented advances have been achieved in hepatobiliary cancer treatment with immune checkpoint blockade(ICB).However,the efficacy of ICB in patients with hepatobiliary malignancies is still limited.Resistance to immunotherapies is often orchestrated by complicated tumor-host-microenvironment inter-actions but could also occur after initial efficacy,mostly when only partial responses are obtained.Clarifi-cation of cancer-resistance mechanisms will be beneficial to provide the rationale for the administration of personalized drugs.Here,we review the factors related to resistance to immune-targeted therapies in hepatobiliary malignancies and discuss the potential strategies for overcoming resistance and future directions of immunotherapy development.
文献关键词:
作者姓名:
Jia Xiong;Qing-Qing Wang
作者机构:
Institute of Immunology,Zhejiang University School of Medicine,Hangzhou 310058,China;The Key Laboratory for Immunity and Inflammatory Diseases of Zhejiang Province,Hangzhou 310058,China
引用格式:
[1]Jia Xiong;Qing-Qing Wang-.Mechanisms and strategies to overcome immunotherapy resistance in hepatobiliary malignancies)[J].国际肝胆胰疾病杂志(英文版),2022(05):430-439
A类:
Clarifi
B类:
Mechanisms,strategies,overcome,immunotherapy,resistance,hepatobiliary,malignancies,Unprecedented,advances,have,been,achieved,cancer,treatment,immune,checkpoint,blockade,ICB,However,efficacy,patients,still,limited,Resistance,immunotherapies,often,orchestrated,by,complicated,tumor,host,microenvironment,inter,actions,but,could,also,occur,after,initial,mostly,when,only,partial,responses,are,obtained,cation,mechanisms,will,beneficial,provide,rationale,administration,personalized,drugs,Here,review,factors,related,targeted,discuss,potential,overcoming,future,directions,development
AB值:
0.660328
相似文献
Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8+T cell-mediated ferroptosis in castration-resistant prostate cancer
Xumin Zhou;Libin Zou;Hangyu Liao;Junqi Luo;Taowei Yang;Jun Wu;Wenbin Chen;Kaihui Wu;Shengren Cen;Daojun Lv;Fangpeng Shu;Yu Yang;Chun Li;Bingkun Li;Xiangming Mao-Department of Urology,Zhujiang Hospital,Southern Medical University,Guangzhou 510280,China;Second Department of Hepatobiliary Surgery,Zhujiang Hospital,Southern Medical University,Guangzhou 510280,China;Department of Urology,Minimally Invasive Surgery Center,the First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510120,China;Department of Urology,Guangzhou Women and Children's Medical Center,Guangzhou Medical University,Guangzhou 510623,China;Department of Urology,Peking University Shenzhen Hospital,Shenzhen 518036,China;Nursing Department,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China
Acquisition of taxane resistance by p53 inactivation in ovarian cancer cells
Changfa Shu;Xi Zheng;Alafate Wuhafu;Danielle Cicka;Sean Doyle;Qiankun Niu;Dacheng Fan;Kun Qian;Andrey A.Ivanov;Yuhong Du;Xiulei Mo;Haian Fu-Department of Pharmacology and Chemical Biology,Emory University School of Medicine,Atlanta,GA 30322,USA;Department of Gynecology and Obstetrics,The Third Xiangya Hospital of Central South University,Changsha 410013,China;Cancer Institute,the Second Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310052,China;The First Affiliated Hospital,Medical School of Xi'an Jiaotong University,Xi'an 710061,China;Emory Chemical Biology Discovery Center,Emory University School of Medicine,Atlanta,GA 30322,USA;Department of Hematology and Medical Oncology and Winship Cancer Institute,Emory University,Atlanta,GA 30322,USA
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。